MUVON Therapeutics announces appointments to its Advisory Board.

Zurich, Switzerland, October 3rd, 2024 – MUVON Therapeutics announces the appointment of Dorothea Ledergerber, PhD, and Christoph Herwig, PhD to its Advisory Board, effective immediately

Deana Mohr, CEO of MUVON Therapeutics AG, expressed her excitement about the new appointments: “Their guidance brings renewed energy to our mission as we move toward key milestones, marking an exciting new chapter for our team. Stay tuned for what’s ahead!”

MUVON Therapeutics announces the addition of Dorothea Ledergerber, PhD to its Advisory Board.

Dorothea Ledergeber is a C-Suite and Board level experienced Pharmacist with extensive practice in research, development, manufacturing and supply of pharmaceutical products. Her  background spans a wide range of accountabilities in the fields of small molecules and cell & gene therapies. Dorothea’s notable achievements include her time at Novartis where she was leading  manufacturing operations in Switzerland, Germany and Ireland. A highlight in her career was the build-up and operational launch of the first commercial Cell & Gene manufacturing facility for Novartis in Europe. Until recently, Dorothea served as Chief Technical Officer at Tigen Pharma, a Startup in the field of autologous cell therapies. Under Dorothea’s leadership, Tigen was pioneering a distributed manufacturing model with the goal of reducing treatment costs and enhancing patient access. Dorothea is a firm believer in cross-cultural and -functional teams to go beyond the beaten industry track.

MUVON Therapeutics announces the addition of Christoph Herwig , PhD to its Advisory Board.

Christoph Herwig is a distinguished bioprocess engineer with a Dipl. Ing. from RWTH Aachen and a PhD in bioprocess identification from EPFL, Switzerland. From 2008 to 2023, he served as a full professor of biochemical engineering at the Vienna University of Technology, where his research specialized in developing data science methods to enhance biopharmaceutical processes, adhering to Process-Analytical-Technology and Quality-by-Design principles. His expertise spans both academia and industry, having played a pivotal role in designing and commissioning large-scale chemical and biopharmaceutical facilities during his tenure at Lonza and other companies.

In 2013, Christoph founded Exputec, a groundbreaking company that led the way in data science software solutions for the biopharma industry. Now part of Körber Pharma, Christoph continues to contribute as a senior scientific advisor. A serial entrepreneur, he is also the Chief Product Officer at Fermify, where he focuses on leveraging precision fermentation for the commercialization of vegan cheese, driving innovation in sustainable food production.